In COSMIC-312 trial, first line #Cabozantinib plus #atezolizumab improved PFS versus #sorafenib for patients with advanced HCC. In this phase 3 randomized RCT, the TKI-based immunotherapy doublet improved the median PFS (6·8 ms vs 4·2 ms) in the sorafenib group (HR 0·63, p=0·0012). Meanwhile, it did not show improvement in median overall survival over sorafenib.
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(22)00326-6/fulltext
.png)